KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortization of GoodwillCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in Working CapitalChange in Working CapitalDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

Teva Pharmaceutical Industries (TEVA) Long-Term Debt Repayments (2017 - 2026)

Teva Pharmaceutical Industries filings provide 12 years of Long-Term Debt Repayments readings, the most recent being $23.0 million for Q1 2026.

  • On a quarterly basis, Long-Term Debt Repayments changed N/A to $23.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $2.8 billion, a 68.62% increase, with the full-year FY2025 number at $4.1 billion, up 150.58% from a year prior.
  • Long-Term Debt Repayments hit $23.0 million in Q1 2026 for Teva Pharmaceutical Industries, down from $444.0 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $3.2 billion in Q1 2023 to a low of $23.0 million in Q1 2026.
  • Median Long-Term Debt Repayments over the past 5 years was $696.5 million (2022), compared with a mean of $992.9 million.
  • Biggest five-year swings in Long-Term Debt Repayments: plummeted 86.32% in 2022 and later skyrocketed 173.97% in 2023.
  • Teva Pharmaceutical Industries' Long-Term Debt Repayments stood at $708.0 million in 2022, then surged by 41.24% to $1.0 billion in 2023, then tumbled by 31.5% to $685.0 million in 2024, then tumbled by 35.18% to $444.0 million in 2025, then tumbled by 94.82% to $23.0 million in 2026.
  • The last three reported values for Long-Term Debt Repayments were $23.0 million (Q1 2026), $444.0 million (Q3 2025), and $2.3 billion (Q2 2025) per Business Quant data.